0001415889-22-012330.txt : 20221209 0001415889-22-012330.hdr.sgml : 20221209 20221209164808 ACCESSION NUMBER: 0001415889-22-012330 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221207 FILED AS OF DATE: 20221209 DATE AS OF CHANGE: 20221209 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Furlow Brenda S. CENTRAL INDEX KEY: 0001443851 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-17272 FILM NUMBER: 221455368 MAIL ADDRESS: STREET 1: 614 MCKINLEY PLACE NE CITY: MINNEAPOLIS STATE: MN ZIP: 55413 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIO-TECHNE Corp CENTRAL INDEX KEY: 0000842023 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 411427402 STATE OF INCORPORATION: MN FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 614 MCKINLEY PL N E CITY: MINNEAPOLIS STATE: MN ZIP: 55413 BUSINESS PHONE: 6123798854 MAIL ADDRESS: STREET 1: 614 MCKINLEY PLACE NE CITY: MINNEAPOLIS STATE: MN ZIP: 55413 FORMER COMPANY: FORMER CONFORMED NAME: TECHNE CORP /MN/ DATE OF NAME CHANGE: 19920703 4 1 form4-12092022_091248.xml X0306 4 2022-12-07 0000842023 BIO-TECHNE Corp TECH 0001443851 Furlow Brenda S. 614 MCKINLEY PL N E MINNEAPOLIS MN 55413 false true false false SVP - GENERAL COUNSEL Common Stock 2022-12-07 4 M 0 800 31.2625 A 26892 D Common Stock 2022-12-07 4 S 0 800 82.0063 D 26092 D Common Stock 2022-12-08 4 M 0 7450 31.2625 A 33542 D Common Stock 2022-12-08 4 S 0 7450 82.1222 D 26092 D Common Stock 5320 I By Trust #1 Common Stock 5320 I By Trust #2 Stock Options (Right to Buy) 31.2625 2022-12-07 4 M 0 800 0 D 2024-08-09 Common Stock 800 37212 D Stock Options (Right to Buy) 31.2625 2022-12-08 4 M 0 7450 0 D 2024-08-09 Common Stock 7450 29762 D Stock Options (Right to Buy) 44.3300 2025-08-08 Common Stock 66248 66248 D Stock Options (Right to Buy) 47.6025 2026-08-07 Common Stock 39872 39872 D Stock Options (Right to Buy) 47.6025 2026-08-07 Common Stock 53160 53160 D Restricted Stock Units Common Stock 6716 6716 D Stock Options (Right to Buy) 66.9675 2027-08-05 Common Stock 29968 29968 D Stock Options (Right to Buy) 66.9675 2027-08-05 Common Stock 39960 39960 D Stock Options (Right to Buy) 66.9675 2027-08-05 Common Stock 33300 33300 D Stock Options (Right to Buy) 66.9675 2027-08-05 Common Stock 33300 33300 D Stock Options (Right to Buy) 93.1100 2022-08-31 2028-03-01 Common Stock 43988 43988 D Restricted Stock Units Common Stock 4668 4668 D Stock Options (Right to Buy) 120.4550 2028-08-06 Common Stock 18240 18240 D Stock Options (Right to Buy) 120.4550 2028-08-06 Common Stock 24320 24320 D Stock Options (Right to Buy) 94.5200 2029-08-15 Common Stock 24664 24664 D Restricted Stock Units Common Stock 7936 7936 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 82.0000 to 82.4900, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Fully exercisable. Options to purchase13,292 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 13,288 shares vest on each of 8/7/2022 and 8/7/2023. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Options to purchase 9,992 shares vest on each of 8/5/2021 and 8/5/2022 and options to purchase 9,988 shares vest on each of 8/5/2023 and 8/5/2024. Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021. Options to purchase 11,100 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023. Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Options to purchase 6,080 shares vest on each of 8/6/2022, 8/6/2023, 8/6/2024 and 8/6/2025. Options to purchase 6,168 shares vest on each of 8/15/2023 and 8/15/2025 and options to purchase 6,164 shares vest on 8/15/2024 and 8/15/2026. 2,644 shares vest on each of 8/15/2023 and 8/15/2025, and 2,648 shares vest on 8/15/2024. On November 28, 2022, the Company completed a four-for-one stock split. All common stock amounts and exercise prices in the filing relating to securities acquired prior to November 28, 2022 have been adjusted to reflect the four-for-one stock split. /s/ Andrew Nick as Attorney-in-Fact for Brenda S. Furlow pursuant to Power of Attorney previously filed 2022-12-09